Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,647 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,647 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03870529 | High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung… | Early Phase 1 | terminated | Mar 12, 2019 | Wake Forest University Health Sciences | Slow accruals | Enrollment / accrual |
| NCT00250848 | Lung Cancer Case Registry and Tissue Resource | — | terminated | Nov 8, 2005 | University of New Mexico | This is not a clinical trial and was inadvertently entered into the system. | Other (stated, no rule matched) |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug… | Phase 1 / Phase 2 | terminated | May 11, 2017 | CytomX Therapeutics | Covid Pandemic; Business Decision to separate Phase 2 to new study | COVID-19 / pandemic |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT04099836 | Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease… | Phase 2 | terminated | Sep 23, 2019 | Duke University | low accrual | Enrollment / accrual |
| NCT03499678 | Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA | — | terminated | Apr 17, 2018 | HKGepitherapeutics | Encountered technical issues with blood plasma samples received from the hospital. | Other (stated, no rule matched) |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in… | Early Phase 1 | withdrawn | Jul 20, 2022 | Mainline Biosciences, Inc. | The study was terminated due to Sponsor decision | Sponsor / business decision |
| NCT01514864 | Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or… | Phase 2 | terminated | Jan 23, 2012 | Bristol-Myers Squibb | Lack of efficacy and slow accrual | Efficacy / futility |
| NCT02531854 | A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients… | Phase 2 | withdrawn | Aug 25, 2015 | Advaxis, Inc. | Study was withdrawn per sponsor decision | Sponsor / business decision |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
| NCT03386929 | Survival Prolongation by Rationale Innovative Genomics(SPRING) | Phase 1 / Phase 2 | terminated | Dec 29, 2017 | Worldwide Innovative Network Association | The SPRING trial had to be early terminated at the end of the Phase 1 portion of the study due to… | Funding |
| NCT05948462 | Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic…(NSCLC) | Phase 2 | withdrawn | Jul 17, 2023 | SCRI Development Innovations, LLC | Study withdrawn by pharmaceutical funding partner | Funding |
| NCT00548730 | Comparison Trial of White Light, Autofluorescence and Narrow Band Imaging Bronchoscopy(NWA) | — | withdrawn | Oct 24, 2007 | Antonios Likourezos | Insufficient enrollment | Enrollment / accrual |
| NCT05066776 | Liquid Biopsy With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules | — | terminated | Oct 4, 2021 | Palo Alto Veterans Institute for Research | Withdrawal by sponsor | Other (stated, no rule matched) |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and… | Phase 1 | terminated | Jan 7, 2016 | SCRI Development Innovations, LLC | Clinical program was discontinued by Novartis | Other (stated, no rule matched) |
| NCT05421936 | Osimertinib for NSCLC With Uncommon EGFR Mutations(UNICORN) | — | suspended | Jun 16, 2022 | Sheba Medical Center | Result summarized and published | Other (stated, no rule matched) |
| NCT04785365 | Long-Term Follow-Up Study of Patients Receiving ATL001 | Phase 2 | terminated | Mar 5, 2021 | Achilles Therapeutics UK Limited | The long-term follow-up of patients is being migrated to the original (parent) study protocols… | Other (stated, no rule matched) |
| NCT04556435 | Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy | — | terminated | Sep 21, 2020 | Breathe BioMedical Inc | Change in the sponsor's business strategy (new focus on breast cancer) | Sponsor / business decision |
| NCT05174468 | Analysis of Volatile Chemicals in Lung Cancer Screen-Eligible Subjects Using Infrared… | — | terminated | Dec 30, 2021 | Breathe BioMedical Inc | Change in sponsor's business strategy (disease focus changed to breast cancer) | Sponsor / business decision |
| NCT02826161 | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in…(CanStem43L) | Phase 3 | terminated | Jul 7, 2016 | Sumitomo Pharma America, Inc. | Change of treatment landscape and evolving standard of care | Other (stated, no rule matched) |
| NCT05905341 | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in… | Phase 1 | withdrawn | Jun 15, 2023 | Pfizer | This decision was based on business considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT03871153 | Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in… | Phase 2 | terminated | Mar 12, 2019 | Greg Durm, MD | Investigator decided to halt study due to low accrual. | Investigator |
| NCT03995667 | Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung… | Phase 2 | terminated | Jun 24, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT03228186 | Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced… | Phase 2 | terminated | Jul 24, 2017 | University of Michigan Rogel Cancer Center | Pharmaceutical company discontinued the study drug. | Sponsor / business decision |
| NCT04308785 | A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small… | Phase 2 | terminated | Mar 16, 2020 | Hoffmann-La Roche | The sponsor's decision was based on the negative results of SKYSCRAPER-02. | Sponsor / business decision |
| NCT05737849 | A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer…(ELEGANT) | — | withdrawn | Feb 21, 2023 | Takeda | Business reason, unrelated to product safety | Safety / toxicity |
| NCT04648189 | Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC | Phase 2 | withdrawn | Dec 1, 2020 | The Netherlands Cancer Institute | One of the participating specialties has decided to no longer cooperate in this research | Other (stated, no rule matched) |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT04739358 | CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC | Phase 1 / Phase 2 | terminated | Feb 4, 2021 | Criterium, Inc. | Study was terminated due to lack of lack of enrollment and difficult patient population. | Enrollment / accrual |
| NCT05161533 | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of… | Phase 2 | withdrawn | Dec 17, 2021 | University of Washington | Closed per SRC Low Accrual Policy. Study closed prior to any participants enrolled. | Enrollment / accrual |
| NCT05180422 | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced,… | Phase 1 / Phase 2 | withdrawn | Jan 6, 2022 | Criterium, Inc. | Lack of enrollment | Enrollment / accrual |
| NCT05863819 | A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)(MEANING-20) | — | withdrawn | May 18, 2023 | Takeda | Business reason, unrelated to product safety | Safety / toxicity |
| NCT02899728 | Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small… | Phase 2 | terminated | Sep 14, 2016 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and… | Phase 1 / Phase 2 | terminated | Dec 8, 2017 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05414123 | A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using…(FORESEE) | — | terminated | Jun 10, 2022 | Biocept, Inc. | The sponsor can no longer financially support the trial. | Funding |
| NCT03951012 | Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC… | — | terminated | May 15, 2019 | Muhammad Furqan | low enrollment and remaining oncologist workload | Enrollment / accrual |
| NCT04040244 | Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis | N/A | terminated | Jul 31, 2019 | Wake Forest University Health Sciences | The PI is requesting this study to be closed due to the departure of the Co-PI who is an integral… | Other (stated, no rule matched) |
| NCT04082988 | Early Response Evaluation in NSCLC Patients Treated With Immunotherapy | N/A | terminated | Sep 10, 2019 | The Netherlands Cancer Institute | The study has been closed due to slow enrollment. | Enrollment / accrual |
| NCT02673021 | MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)(MARK 1A) | N/A | terminated | Feb 3, 2016 | Mayo Clinic | Funding suspended prior to completing enrollment of all participants. | Enrollment / accrual |
| NCT00769652 | Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer,… | N/A | terminated | Oct 9, 2008 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT04917224 | Study of LUNG Stereotactic Adaptive Ablative Radiotherapy(LUNG STAAR) | N/A | withdrawn | Jun 8, 2021 | Baptist Health South Florida | ViewRay (funding agency) has filed under Chapter 11, U.S. Bankruptcy Code. ViewRay's clinical… | Enrollment / accrual |
| NCT04989283 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy… | Phase 2 | withdrawn | Aug 4, 2021 | National Cancer Institute (NCI) | Due to no accrual | Enrollment / accrual |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung…(ENSIGN) | Phase 2 | terminated | Jul 13, 2016 | Eric Bernicker, MD | Lack of funding | Funding |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Phase 1 | terminated | May 27, 2022 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT03425006 | Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer | Phase 2 | terminated | Feb 7, 2018 | University of Pennsylvania | Administrative reasons | Other (stated, no rule matched) |
| NCT05045404 | Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small… | Phase 2 | withdrawn | Sep 16, 2021 | M.D. Anderson Cancer Center | Study closed due to funding, 0 patient accrual. | Enrollment / accrual |
| NCT05287971 | Standard of Care Lifestyle Support for Stage III NSCLC Patients(PERCUSSION) | — | withdrawn | Mar 18, 2022 | Maastricht Radiation Oncology | Never started | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 9, 2024source: clinicaltrials